Show simple item record

dc.contributor.authorNenna, Raffaella
dc.contributor.authorZhai, Jing
dc.contributor.authorPackard, Samuel E
dc.contributor.authorSpangenberg, Amber
dc.contributor.authorSherrill, Duane L
dc.contributor.authorMartinez, Fernando D
dc.contributor.authorHalonen, Marilyn
dc.contributor.authorGuerra, Stefano
dc.date.accessioned2020-11-07T01:31:05Z
dc.date.available2020-11-07T01:31:05Z
dc.date.issued2020-04-27
dc.identifier.citationNenna, R., Zhai, J., Packard, S. E., Spangenberg, A., Sherrill, D. L., Martinez, F. D., ... & Guerra, S. (2020). High cytomegalovirus serology and subsequent COPD-related mortality: a longitudinal study. ERJ open research, 6(2).en_US
dc.identifier.issn2312-0541
dc.identifier.pmid32363208
dc.identifier.doi10.1183/23120541.00062-2020
dc.identifier.urihttp://hdl.handle.net/10150/648137
dc.description.abstractBackground: Positive serology for cytomegalovirus (CMV) has been associated with all-cause mortality risk but its role in COPD mortality is unknown. The objective of the present study was to assess the relationship between CMV serology and COPD mortality. Methods: We analysed data from 806 participants in the Tucson Epidemiological Study of Airway Obstructive Disease who, at enrolment, were aged 28-70 years and had completed lung function tests. We tested CMV serology in sera from enrolment and defined "high CMV serology" as being in the highest tertile. Vital status, date and cause of death were assessed through death certificates and/or linkage with the National Death Index up to January 2017. The association of CMV serology with all-cause and causespecific mortality risk was tested in Cox models adjusted for age, sex, level of education, body mass index, smoking status and pack-years. Results: High CMV serology was marginally associated with all-cause mortality (p=0.071) but the effect was inversely dependent on age, with the association being much stronger among participants <55 years than among participants.55 years at enrolment ( p-value for CMV-by-age interaction <0.001). Compared with low CMV serology, high CMV serology was associated with mortality from COPD among all subjects (adjusted hazard ratio (HR) 2.38, 95% CI 1.11-5.08; p=0.025) and particularly in subjects <55 years old at enrolment (HR 5.40, 95% CI 1.73-16.9; p=0.004). Consistent with these results, high CMV serology also predicted mortality risk among subjects who already had airflow limitation at enrolment (HR 2.10, 95% CI 1.20-3.68; p=0.009). Conclusions: We report a strong relationship between CMV serology and the risk of dying from COPD, and thus identify a novel risk factor for COPD mortality.en_US
dc.language.isoenen_US
dc.publisherEUROPEAN RESPIRATORY SOC JOURNALS LTDen_US
dc.rightsCopyright © ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/en_US
dc.titleHigh cytomegalovirus serology and subsequent COPD-related mortality: a longitudinal studyen_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Asthma & Airway Dis Res Ctren_US
dc.contributor.departmentUniv Arizona, Coll Med, Dept Pharmacolen_US
dc.identifier.journalERJ OPEN RESEARCHen_US
dc.description.noteOpen access journalen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleERJ open research
dc.source.volume6
dc.source.issue2
refterms.dateFOA2020-11-07T01:31:16Z
dc.source.countryEngland


Files in this item

Thumbnail
Name:
00062-2020.full.pdf
Size:
550.5Kb
Format:
PDF
Description:
Final Published Version
Thumbnail
Name:
inline-supplementary-material-1.pdf
Size:
220.6Kb
Format:
PDF
Description:
Supplementary Material

This item appears in the following Collection(s)

Show simple item record

Copyright © ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Except where otherwise noted, this item's license is described as Copyright © ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.